Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer.

Evidence is accumulating supporting gender-related differences in the development of colonic carcinomas. Sex steroid hormone receptors are expressed in the colon and interact with epidermal growth factor receptor (EGFR), a gene widely expressed in colonic tissue. Increased EGFR expression is linked with poor prognosis in colon cancer. Within the EGFR gene there are two functional polymorphisms of interest: a polymorphism located at codon 497 (HER-1 R497K) and a dinucleotide (CA)(n) repeat polymorphism located within intron 1. These germ-line polymorphisms of EGFR were analyzed in genomic DNA from 318 metastatic colon cancer patients, 177 males and 141 females, collected from 1992 to 2003. Gender-related survival differences were associated with the HER-1 R497K polymorphism (P(interaction) = 0.003). Females with the HER-1 497 Arg/Arg variant had better overall survival (OS) when compared with the Lys/Lys and/or Lys/Arg variants. In males the opposite was true. The EGFR dinucleotide (CA)(n) repeat also trended with a gender-related OS difference (P(interaction) = 0.11). Females with both short <20 (CA)(n) repeat alleles had better OS than those with any long >or=20 (CA)(n) repeats. In males the opposite was true. Combination analysis of the two polymorphisms taken together also revealed the same gender-related survival difference (P(interaction) = 0.002). These associations were observed using multivariable analysis. The two polymorphisms were not in linkage disequilibrium and are independent of one another. This study supports the role of functional EGFR polymorphisms as independent prognostic markers in metastatic colon cancer. As a prognostic factor, these variants had opposite prognostic implications based on gender.

[1]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[2]  T. Gorlia,et al.  Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963 , 2005 .

[3]  S. Groshen,et al.  Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  E. Baldi,et al.  The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells , 2004, Steroids.

[5]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Sandler,et al.  Epidermal growth factor receptor: a promising target in solid tumours. , 2004, Cancer treatment reviews.

[7]  E. Levin Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. , 2003, Molecular endocrinology.

[8]  E. Cook,et al.  Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  C. Folwaczny,et al.  Candidate Genes Colocalized to Linkage Regions in Inflammatory Bowel Disease , 2002, Digestion.

[10]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[11]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[12]  David Joseph,et al.  Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer , 2000, The Lancet.

[13]  Daniel S. Miller,et al.  The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer , 2000, Cancer.

[14]  N. Fortunati,et al.  Altered expression of androgen‐receptor isoforms in human colon‐cancer tissues , 2000, International journal of cancer.

[15]  R. Simon,et al.  Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. , 2000, Cancer research.

[16]  K. Zänker,et al.  Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.

[17]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis , 1999 .

[18]  M. Brandi,et al.  Functional estrogen receptor beta in colon cancer cells. , 1999, Biochemical and biophysical research communications.

[19]  Daniel S. Miller,et al.  Cancer incidence and mortality, 1973‐1995 , 1998 .

[20]  M. Korc,et al.  A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Jacobson,et al.  Gender and colorectal cancer. , 1993, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[22]  N. Quenville,et al.  Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki‐67 , 1992, Journal of surgical oncology.

[23]  M. Graffar [Modern epidemiology]. , 1971, Bruxelles medical.